Safety review: dose optimization of somatostatin analogs in patients with acromegaly and neuroendocrine tumors.
about
Gastrointestinal neuroendocrine tumors treated with high dose octreotide-LAR: a systematic literature reviewTherapy for metastatic pancreatic neuroendocrine tumors.Combined derivatization and high-performance liquid chromatography with fluorescence and ultraviolet detection for simultaneous analysis of octreotide and gabexate mesylate metabolite in human pancreatic juice samples.The expanding role of somatostatin analogs in the management of neuroendocrine tumors.A review of the use of somatostatin analogs in oncologyMulticentre, open-label, randomised, parallel-group, superiority study to compare the efficacy of octreotide therapy 40 mg monthly versus standard of care in patients with refractory anaemia due to gastrointestinal bleeding from small bowel angiodysThe role of primary pharmacological therapy in acromegaly.Management options for persistent postoperative acromegaly.Emerging drugs for acromegaly.Escalated-dose somatostatin analogues for antiproliferative effect in GEPNETS: a systematic review.Effect of everolimus on the pharmacokinetics of octreotide long-acting repeatable in patients with advanced neuroendocrine tumors: An analysis of the randomized phase III RADIANT-2 trial.Octreotide long-acting repeatable in the treatment of neuroendocrine tumors: patient selection and perspectives.Long-term safety of long-acting octreotide in patients with diabetic retinopathy: results of pooled data from 2 randomized, double-blind, placebo-controlled phase 3 studies.A long-term follow-up study of eighteen patients with thyrotrophin-secreting pituitary adenomas.A rapid hydrolysis method and DABS-Cl derivatization for complete amino acid analysis of octreotide acetate by reversed phase HPLC.Expression of somatostatin and its receptor 1-5 in endometriotic tissues and cells
P2860
Q26866246-9172D099-7697-4AC5-A8DE-913CE817EC88Q34357869-C240D890-45CE-43A5-A53E-5D08156732C0Q35375598-2D514FCA-2242-4EB0-B71C-5E54584CC809Q36347272-3AC14273-8B2A-48C9-8BF4-F8CEB9BC2E75Q36833161-8F77B4CA-07BA-45AE-B797-EFD65D7A70CBQ37271484-865BB0E1-D362-44E4-9B57-696AB18F623AQ37531005-C179A1CE-DE61-43DD-A6B9-E99B9B2BB315Q38049832-B1592B24-F8AE-492D-866B-F3122CB14D47Q38176659-02E236EB-5203-44D1-B00B-1803176271EEQ39447034-3F088A76-C510-45D3-862E-343C51EC7C2AQ40403300-D07AC0C6-78D0-49EE-9C67-8B7268775D68Q47097042-AE100B02-6A21-45A0-8D92-3DCD4E02ED30Q47632942-A5006393-7D0D-457B-B3F7-1163BE2194AFQ48018768-A0540B8C-DF57-4C8C-A3C4-AF48F90DE689Q49055089-2B431A2D-A6EE-4F15-A8D8-2A6C9FF65EF9Q58552314-EB6E2D94-E0A1-44BB-94D5-6F6D269AA97B
P2860
Safety review: dose optimization of somatostatin analogs in patients with acromegaly and neuroendocrine tumors.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Safety review: dose optimizati ...... aly and neuroendocrine tumors.
@en
Safety review: dose optimizati ...... aly and neuroendocrine tumors.
@nl
type
label
Safety review: dose optimizati ...... aly and neuroendocrine tumors.
@en
Safety review: dose optimizati ...... aly and neuroendocrine tumors.
@nl
prefLabel
Safety review: dose optimizati ...... aly and neuroendocrine tumors.
@en
Safety review: dose optimizati ...... aly and neuroendocrine tumors.
@nl
P2860
P1433
P1476
Safety review: dose optimizati ...... aly and neuroendocrine tumors.
@en
P2093
Lowell Anthony
William H Ludlam
P2860
P2888
P304
P356
10.1007/S12325-011-0062-9
P407
P577
2011-09-28T00:00:00Z